Iron could promote free radical formation, which may lead to injury of the arterial wall and atherosclerosis. Blood donation may reduce cardiovascular risk by lowering body iron status. We collected data on blood donation history and intima-media thickness of the common carotid artery (CIMT) in 819 subjects (50-70 years), who were recruited from municipal and blood bank registries in The Netherlands. Serum iron parameters were assessed, including non-transferrin bound iron (NTBI) that has recently been found in conditions of iron overload. Serum ferritin was lower in current donors (n=443; 44 microg/L) than in ex-donors (n=120; 114 microg/L) and never-donors (n=256; 124 microg/L, P for trend <0.001). For NTBI, values were 2.33, 2.54, and 2.51 micromol/L, respectively (P<0.05). CIMT was slightly reduced in frequent donors (i.e., > or =49 times during life or > or =2 times per year), although not statistically significant. CIMT was not significantly related to NTBI. Frequent blood donation, resulting in lowered body iron, might give some protection against accelerated atherosclerosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.atherosclerosis.2007.01.031 | DOI Listing |
Alzheimers Res Ther
March 2025
Department of Biomedical Engineering, University of California, Irvine, CA, USA.
Background: Nicotinamide, a form of B3 vitamin, is an NAD precursor that reduces pTau levels via histone deacetylase inhibition in murine models of Alzheimer's disease (AD). A recent phase 2a randomized placebo-controlled trial tested high-dose oral nicotinamide for the treatment of early AD. While nicotinamide demonstrated good safety and tolerability, it did not significantly lower CSF pTau, the primary biomarker endpoint of the study.
View Article and Find Full Text PDFBlood
March 2025
German Cancer Research Center, Heidelberg, Germany.
Donor blood saves lives, yet the potential impact of recurrent large-volume phlebotomy on donor health and hematopoietic stem cells (HSCs) remains largely unexplored. In our study, we conducted a comprehensive screening of 217 older male volunteer donors with a history of extensive blood donation (>100 life-time donations) to investigate the phenomenon of clonal hematopoiesis (CH). No significant difference in the overall incidence of CH was found in frequent donors (FD) compared to sporadic donors (<10 life-time donations, 212 donors).
View Article and Find Full Text PDFAm J Transplant
March 2025
Dept. of Pediatrics; University of Alberta, Edmonton, Alberta, Canada; Alberta Transplant Institute and Canadian Donation and Transplantation Research Program, Edmonton, Canada; Dept. of Pediatrics, University of Alberta, Edmonton, Alberta, Canada; Depts. of Surgery, and Laboratory Medicine & Pathology, University of Alberta, Edmonton, Alberta, Canada. Electronic address:
ABO antibodies pose barriers in transplantation but remain poorly studied. We investigated anti-A natural antibodies (nAbs) and induced antibodies (iAbs) in wild-type (WT), CD19KO, and CD22KO mice in the context of MHC-syngeneic or MHC-allogeneic stimulation by ABO-A blood cell membranes (BCM) from A-transgenic mice, or xenogeneic human (Hu-A) BCM. CD19KO mice failed to produce anti-A nAbs and iAbs.
View Article and Find Full Text PDFHepatobiliary Pancreat Dis Int
February 2025
Department of Hepatopancreatic Surgery, Foshan First People's Hospital, Foshan 528010, China.
Background: The use of grafts from donation after circulatory death (DCD) overcomes the inadequate donor organ supply. Our team developed a transportable dual hypothermic oxygenated machine perfusion (DHOPE) device, which initiates DHOPE at a recipient center to reduce static cold storage (SCS) time and the risk of graft failure in DCD liver transplantation.
Methods: Six porcine livers per group with 30 min of warm ischemia exposure were preserved via SCS or DHOPE for 6 h and then reperfused for 12 h with whole blood to mimic transplantation.
Iran J Allergy Asthma Immunol
February 2025
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Administering human leukocyte antigen (HLA)-compatible platelets is a tactic for treating patients with poor responses to random platelet injections. HLA-matched platelet provision requires many donors with HLA-typed and organized information. This study, the first of its kind in Iran, aimed to develop a registry system of HLA-typed platelet donors to facilitate the provision of compatible platelets to patients, leveraging the diversity of HLA alleles across Iran's various provinces.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!